PEG-Hemoglobin Trial Underway

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

PISCATAWAY, NJ--Enzon, Inc. has begun a multidose, multicen-ter clinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin, in cancer patients receiving radiation therapy. The agent was developed as a radiosensitizer to increase oxygenation of hypoxic tumors cells that may be resistant to irradiation. Patients will receive once-a-week infusions of PEG-hemoglobin followed by 5 days of radiation therapy, repeated weekly for 3 weeks.

PISCATAWAY, NJ--Enzon, Inc. has begun a multidose, multicen-terclinical trial of its hemoglobin-based oxygen carrier, PEG-hemoglobin,in cancer patients receiving radiation therapy. The agent wasdeveloped as a radiosensitizer to increase oxygenation of hypoxictumors cells that may be resistant to irradiation. Patients willreceive once-a-week infusions of PEG-hemoglobin followed by 5days of radiation therapy, repeated weekly for 3 weeks.

Articles in this issue
Chemo Improves Pain Relief in Advanced Prostate Cancer
Multimedia Computer Program Patiently Answers Young Cancer Patients' Questions
NCCR Urges Congress to Support Senate Bill for Cancer Research
Researchers Propose New Treatment Guidelines for HIV
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Anderson
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samples
New Thinking on HIV Progression Leads to New Strategies
Hospitals Told Not to Capitate for 'Wrong' Reasons
More Study Needed of Possible Carcinogenesis of Winter Gas Additive
President Makes NCAB Appointments
Algorithm Identifies Women at Risk of Ovarian Cancer
Three Million a Year Die From Tobacco-Related Causes
Marketing of Cancer Services Must Include All Payer Modalities
Dr. Kessler Corrects Misapprehension That The FDA Cannot Regulate Tobacco Products
New Surgical Techniques May Reduce Impotence, Incontinence
Recent Videos
The approval of daratumumab validates the notion of using limited therapy to help delay progression from smoldering disease to multiple myeloma.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content
The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

Russ Conroy
November 6th 2025
Article

The safety profile of palazestrant plus ribociclib in a phase 1b trial was comparable with prior reports of each individual agent.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

UGN-103 Exhibits Durable Responses in Recurrent LG-IR-NMIBC

Roman Fabbricatore
November 6th 2025
Article

The FDA agreed that data from the UTOPIA trial, with UGN-103 demonstrating a 77.8% 3-month CR rate in patients with LG-IR-NMIBC, support an NDA submission.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

Trial Assessing Savolitinib/Osimertinib in NSCLC Completes Enrollment

Roman Fabbricatore
November 5th 2025
Article

Topline data are expected to be available in the first half of 2026 after the submission of results for presentation at a medical conference.

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.